US2003148994A1PendingUtilityA1

Hemostatic composition

62
Priority: Nov 13, 2001Filed: Oct 9, 2002Published: Aug 7, 2003
Est. expiryNov 13, 2021(expired)· nominal 20-yr term from priority
Inventors:Melvin E. Levinson
A61K 31/715A61B 17/0057A61F 13/00A61F 2013/00412A61F 2013/00472A61L 2400/04
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A hemostatic composition for effecting hemostasis at a hemorrhaging site comprises a hemostatically effective amount of cationic substance and a base, wherein the base is in a form of an ointment, a cream, a gel, a foam or a paste, and wherein the cationic substance is substantially uniformly dispersed in the base. The method of preparing the hemostatic composition includes admixing an aqueous solution of a cationic substance and the base, and freeze-drying the mixture to remove substantially all of the water to yield a viscous water soluble composition of fine particles of cationic which is substantially uniformly dispersed throughout the base, and the method of its use to provide hemostasis to a hemorrhaging site of a mammal.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A hemostatic composition comprising: 
 a hemostatically effective amount of hemostatic cationic substance; and    a base, wherein said hemostatic cationic substance is substantially uniformly dispersed in said base, and wherein said base is in a form selected from the group consisting of an ointment, a cream, a gel, a foam, and a paste.    
     
     
         2 . The composition of  claim 1 , wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,  
     
     
         3 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.  
     
     
         4 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-D-glucosamine.  
     
     
         5 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.  
     
     
         6 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.  
     
     
         7 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         8 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         9 . The composition of  claim 2 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         10 . The composition of  claim 2 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         11 . The composition of  claim 1 , wherein said base is water-soluble.  
     
     
         12 . The composition of  claim 1  further includes an anti-microbial material.  
     
     
         13 . A method for making a hemostatic composition comprising: 
 mixing a hemostatically effective amount of hemostatic cationic substance and a base, wherein said base is in a form selected from the group consisting of an ointment, a cream, a gel, a foam, and a paste.    
     
     
         14 . The method of  claim 13 , wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,  
     
     
         15 . The method of  claim 14 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.  
     
     
         16 . The method of  claim 14 , wherein the biopolymer of glucosamine is poly-D-glucosamine.  
     
     
         17 . The method of  claim 14 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.  
     
     
         18 . The method of  claim 14 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.  
     
     
         19 . The method of  claim 14 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         20 . The method of  claim 14 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         21 . The method of  claim 14 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         22 . The method of  claim 14 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         23 . The method of  claim 13 , wherein said base is water-soluble.  
     
     
         24 . The method of  claim 13  further includes a step of mixing an anti-microbial material in said composition.  
     
     
         25 . A method for effecting hemostatic composition at a hemorrhaging site in a mammal comprising: 
 A). forming a hemostatic composition by mixing a hemostatically effective amount of hemostatic cationic substances and a base, wherein said base is in a form selected from the group consisting of an ointment, a cream, a gel, a foam, and a paste; and    B). applying a hemostatically effective amount of said hemostatic composition to the hemorrhaging site of the mammal.    
     
     
         26 . The method of  claim 25  further includes maintaining pressure for a predetermined time on the hemorrhaging site after applying said hemostatic composition to the hemorrhaging site of the mammal.  
     
     
         27 . The method of  claim 25 , wherein the hemostatic cationic substance comprises a biopolymer of glucosamine,  
     
     
         28 . The method of  claim 27 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine.  
     
     
         29 . The method of  claim 27 , wherein the biopolymer of glucosamine is poly-D-glucosamine.  
     
     
         30 . The method of  claim 27 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine.  
     
     
         31 . The method of  claim 27 , wherein the biopolymer of glucosamine is an acetate salt of poly-D-glucosamine.  
     
     
         32 . The method of  claim 27 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         33 . The method of  claim 27 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and poly-D-glucosamine.  
     
     
         34 . The method of  claim 27 , wherein the biopolymer of glucosamine is an acetate salt of poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.  
     
     
         35 . The method of  claim 27 , wherein the biopolymer of glucosamine is poly-N-acetylglucosamine and an acetate salt of poly-D-glucosamine.

Join the waitlist — get patent alerts

Track US2003148994A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.